Efficacy of thrombomodulin alpha (rTM) in therapy for disseminated intravascular coagulation (DIC) with acute pancreatitis

Efficacy of thrombomodulin alpha (rTM) in therapy for disseminated intravascular coagulation (DIC) with acute pancreatitis - Efficacy of rTM for DIC with acute pancreatitis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011761

Enrollment

Registered

2013-09-13

Start date

2013-09-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

DIC with acute pancreatitis

Interventions

Administration of thrombomodulin alpha

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients who suffer from acute pancreatitis with acute DIC score more than 4 points 2. The agreed patients with their own decisions under the sufficient explanation

Exclusion criteria

Exclusion criteria: 1. Patients who have intracranial bleeding, pulmonary hemorrhage, hemorrhage of digestive tract 2. Patients with a history of hypersensitivity to rTM 3. Pregnant or supposed to be pregnant patients

Design outcomes

Primary

Measure	Time frame
28-day mortality	—

Secondary

Measure	Time frame
secession rate of acute DIC score, the change of laboratory values, safety assessment	—

Countries

Japan

Contacts

Public ContactKengo Tomita

National Defense Medical College Department of Internal Medicine

kengo@ndmc.ac.jp04-2995-1609

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026